These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36913542)

  • 61. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database.
    Lo SC; Kornelius E; Liao PL; Huang JY; Yang YS; Huang CN
    Diabetes Res Clin Pract; 2023 Jun; 200():110685. PubMed ID: 37100230
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
    Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
    Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.
    Longato E; Di Camillo B; Sparacino G; Gubian L; Avogaro A; Fadini GP
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32591373
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):843-849. PubMed ID: 34276009
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
    Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis.
    Abiru N; Shoji S; Kosakai Y; Snijder R; Asakawa K; Rokuda M
    Diabetes Res Clin Pract; 2022 Aug; 190():109973. PubMed ID: 35760156
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
    Desai RJ; Glynn RJ; Everett BM; Schneeweiss S; Wexler DJ; Bessette LG; Déruaz-Luyet A; Vedin O; Brodovicz K; Patorno E
    Am Heart J; 2022 Dec; 254():203-215. PubMed ID: 36150454
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Type 2 Diabetes Mellitus: GLP1 Receptor Agonists and SGLT2 Inhibitors in Patients Referred to Ambulatory Consultant Cardiology Clinics.
    Antonelli D; Rabkin Y; Turgeman Y; Jabaren M
    Isr Med Assoc J; 2023 Feb; 25(2):143-146. PubMed ID: 36841985
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.